CLDX CELLDEX THERAPEUTICS INC NEW

Ownership history in Commodore Capital LP  ·  19 quarters on record

This page tracks every 13F SEC filing in which Commodore Capital LP reported a position in CELLDEX THERAPEUTICS INC NEW (CLDX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
4.96% (2025 Q2)
Avg. % of fund
3.23%
First filed
2020 Q4
Last filed
2025 Q4
Quarters held
19
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 2,565,000 -463,335 -15.3% 4.64% $69.7M $27.16
2025 Q3 REDUCED 3,028,335 -421,665 -12.2% 3.82% $78.3M $25.87
2025 Q2 ADDED 3,450,000 +250,000 +7.8% 4.96% $70.2M $20.35
2025 Q1 ADDED 3,200,000 +1,581,063 +97.7% 4.28% $58.1M $18.15
15 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    CLDX price (monthly, adj. close)
← Back to Commodore Capital LP Holdings